期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
7例生物潜能未定非典型神经纤维瘤的临床病理学特征 被引量:1
1
作者 张笑盈 李春梅 +2 位作者 张铭 饶晓松 任玉波 《中国肿瘤临床》 CAS CSCD 北大核心 2021年第7期351-355,共5页
目的:探讨生物潜能未定非典型神经纤维瘤(atypical neurofibromatous neoplasm of uncertain biologic potential,ANNUBP)的临床病理特征、免疫表型、分子遗传学改变。方法:分析2014年12月至2020年8月收集于北京大学国际医院病理诊断为... 目的:探讨生物潜能未定非典型神经纤维瘤(atypical neurofibromatous neoplasm of uncertain biologic potential,ANNUBP)的临床病理特征、免疫表型、分子遗传学改变。方法:分析2014年12月至2020年8月收集于北京大学国际医院病理诊断为非典型或富于细胞性神经纤维瘤14例患者的临床资料,其中7例具有ANNUBP的特征,光镜观察肿瘤细胞形态、免疫表型特征、并进行总结。结果:ANNUBP中男性5例,女性2例,年龄14~44岁(平均年龄27岁,中位年龄27岁);6例位于腹膜后,1例位于头颈部,最大径4.5~21.5 cm,平均11.0 cm,界限较清。镜下肿瘤细胞可见细胞异型性、丰富密集、失去神经纤维瘤结构和/或核分裂像增加(>1/50 HPF和<3/10 HPF);其中4例多次复发,2例进展为恶性外周神经鞘膜瘤(malignant peripheral nerve sheath tumor,MPNST),1例无瘤生存,复发率85.71%(6/7),恶变率28.57%(2/7);S-100、SOX-10、H3K27Me3在7例中均弥漫强表达,1例CD34染色显示网状结构消失,Ki-67增殖指数<2%~5%。结论:ANNUBP是具有较高复发率和恶变率的肿瘤,术后应结予相应的辅助治疗,并密切随访,同时也应避免过度治疗;结合免疫组织化学,有助于其诊断和鉴别诊断。 展开更多
关键词 生物潜能未定非典型神经纤维瘤 复发 恶性外周神经鞘膜瘤
下载PDF
Overexpression of ASPH protein predicts poor outcomes in retroperitoneal liposarcoma patients
2
作者 Mengmeng Xiao Xiaobing Chen +3 位作者 Weida Chen Lihua Wang xiaosong rao Chenghua Luo 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第17期2113-2115,共3页
To the Editor:Liposarcoma is a common subtype of retroperitoneal sarcoma.Due to the complicated anatomical heterogeneity of retroperitoneal liposarcoma(RPLS),it compresses and invades adjacent important organs,and mas... To the Editor:Liposarcoma is a common subtype of retroperitoneal sarcoma.Due to the complicated anatomical heterogeneity of retroperitoneal liposarcoma(RPLS),it compresses and invades adjacent important organs,and massive bleeding frequently occurs during surgery.Therefore,a combined visceral resection is required,which means that RPLS surgery has greater difficulty and a lower complete resection rate compared to surgeries for other solid tumors.Although in our previous studies we found that intraperitoneal thermoperfusion chemotherapy including cisplatin may improve the prognosis of patients with RPLS,[1]surgery is the most effective treatment for RPLS,and adjuvant therapies have shown almost ineffective.There is a paucity of research focusing specifically on molecular mechanisms underlying RPLS pathogenesis.Consequently,no diagnostic biomarkers,druggable targets,or prognostic factors are available for RPLS. 展开更多
关键词 SARCOMA PATIENTS SURGERY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部